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Objectives: An international series of pulmonary retransplantation was updated 
to determine the factors associated with pulmonary function, bronchiolitis 
obliterans yndrome stage, and survival after operation. Methods: One hun- 
dred sixty patients underwent retransplantation in 35 centers from 1985 to 
1995. Logistic regression methods were used to determine variables associated 
with 3-month and 2-year survival after retransplantation. Values of forced 
expiratory volume in 1 second were contrasted between groups by unpaired, 
two-tailed t tests. Results: The median follow-up in surviving recipients was 780 
days. Actuarial survival was 45% - 4%, 41% + 4%, and 33% -+ 4% at 1, 2, and 
3 years, respectively. On multivariable analysis, the only predictor of 3-month 
survival was preoperative ambulatory status (p = 0.005), whereas center 
experience with at least five pulmonary retransplantations was the sole 
predictor of 2-year survival (p = 0.04). The prevalence of stage 3 (severe) 
bronchiolitis obliterans yndrome was 12% at 1 year, 15% at 2 years, and 33% 
at 3 years after etransplantation. Retransplant recipients with stage 3 
bronchiolitis obliterans yndrome at 1 year had a significantly worse actuarial 
survival than those with stages 0 to 2 (p < 0.01). By 3 years after retransplan- 
tation, the forced expiratory volume in 1 second was significantly lower in 
patients who underwent reoperation because of obliterative bronchiolitis than 
in patients who underwent retransplantation because of acute graft ailure or 
an airway complication (p = 0.02). Only 31% of patients who underwent 
retransplantation because of obliterative bronchiolitis were free of bronchioli- 
tis obliterans yndrome at 3 years versus 83% of patients who underwent 
retransplantation because of other indications (!7 = 0.02). Conclusions: Preop- 
erative ambulatory status predicts early survival and center volume predicts 
intermediate-term outcome after retransplantation. Improved management 
strategies are necessary to prevent the development of progressive graft 
dysfunction after retransplantation for obliterative bronchiolitis. (J Thorac 
Cardiovasc Surg 1996;112:1504-14) 
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D espite significant advances in donor manage- ment I and lung graft preservation 2 in recent 
years, the number of reported lung transplantation 
procedures has plateaued since 1993. 3* Although 
the results of primary lung transplantation have 
improved, 4 lung transplant recipients remain vulner- 
able to severe early graft dysfunction, intractable 
airway healing problems, and obliterative bronchi- 
olitis (OB). Since the late 1980s an increasing num- 
ber of pulmonary retransplantations have been per- 
*Cooper JD, St. Louis International Lung Transplant Registry. 
September 1995 report. St. Louis, Missouri. 
Copyright © 1996 by Mosby-Year Book, Inc. 
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Table I. Association of recipient variables with 3-month and 2-year survival after pulmonary retransplantation 
Variable 
Three-month survival 
Marginal analysis Multivariable analysis 
Two-year survival 
Marginal analysis Multivariable analysis 
Adjusted Adjusted 
Odds ratio odds ratio Odds ratio odds ratio 
(95% CI) p Value (95% CI) p Value (95% CI) p Value (95% CI) p Value 
Age 
As a continuous variable 
-<40 vs >40 yr 
* 0.56 t NS * 0.63 t NS 
1.23 0.52 t NS 1.09 0.92 t NS 
(0.66, 2.31) (0.45, 2.04) 
Female sex 0.90 0.73 t NS 1.35 0.44 t NS 
(0.48, 1.69) (0.64, 2.87) 
Original diagnosis * 0.40 ? NS * 0.47 t NS 
Indication for retransplanta- 
tion 
All indications * 0.42 t NS * 0.44 t NS 
OB vs non-OB 1.36 0.34 t NS 0.69 0.33 t NS 
(0.72, 2.57) (0.33, 1.46) 
Ambulatory before retrans- 2.42 0.01 2.97 0.005 1.61 0.25 t NS 
plantation (1.19, 4.95) (1.37, 6.40) (0.72, 3.61) 
Ventilator support before 0.64 0.17 t NS 0.94 0.87 t NS 
retransplantation (0.34, 1.21) (0.44, 2.00) 
Recipient CMV positivity 0.72 0.36 t NS 0.96 0.92 t NS 
(0.36, 1.45) (0.41, 2.22) 
Waiting time 
As a continuous variable * 0.62 t NS * 0.41 t NS 
>2 wk vs -<2 wk 1.45 0.28 t NS 1.22 0.62 t NS 
(0.74, 2.86) (0.55, 2.73) 
Interval between transplants 
Continuous * 0.05 t NS * 0.76 t NS 
>2 yr vs -<2 yr 1.79 0.15 t NS 1.07 0.90 t NS 
(0.82, 3.89) (0.33, 2.62) 
Odds ratios and adjusted odds ratios >1.0 indicate increased survival, whereas ratios <1.0 indicate decreased survival at 3 months and 2 years after 
retransplantation. C/, confidence interval; NS, not significant on multivariable analysis; CMV, cytomegalovirus; OB,obliterative bronchiolitis. 
*Odds ratio not calculated because variable has more than two categories. 
tAdjusted odds ratio not calculated because variable does not enter into multivariable model. 
formed because of acute or chronic graft failure. 5-14 
In view of the marked scarcity of suitable donor lung 
grafts, the pulmonary retransplant registry was es- 
tablished in 1991 with the goal of determining, via a 
multiinstitutional analysis, the outcome and predic- 
tors of survival after pulmonary retransplantation. 5 
Recently, with an increasing duration of follow-up in 
retransplant recipients, the registry has focused on 
pulmonary function and clinical status in the inter- 
mediate term after operation. 8 After a significant 
number of patients reached the third and fourth 
anniversaries of retransplantation, the registry data 
were updated to determine the recurrence rate of 
OB and the factors associated with survival and 
pulmonary function in the intermediate term after 
retransplantation. 
Patients and methods 
During the past 5 years patients undergoing pulmonary 
retransplantation have been recruited to the registry by 
means of a standardized study questionnaire. Patients 
who have undergone repeat heart-lung transplantation or 
a heart-lung transplantation after a previous pulmonary 
transplantation have been excluded. 5 Once registered, all 
patients are followed up prospectively, with 6- to 12- 
month updates of clinical status and pulmonary function. 
For the purposes of this report, the status of all registry 
patients was updated in October 1995. Patients who 
underwent retransplantat ion for any indication were in- 
cluded in the study cohort. 
The 17 variables listed in Tables I and II were recorded 
for each patient. An ambulatory recipient was defined as 
a pat ient who was able to walk at least 50 meters, with or 
without assistance, immediately before retransplantation. 
Study form results were incorporated into the pulmonary 
retransplant database with the use of the FoxPro database 
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Table  II .  Association of  donor and operative variables with 3-month and 2-year survival after pulmonary 
retransplantation 
Three-month survival 
Marginal analysis Multivariable analysis 
Two-year survival 
Marginal analysis Muhivariable analysis 
Adjusted 
Odds ratio Adjusted Odds ratio odds ratio 
Variable (95% CI) p Value odds ratio p Value (95% CI) p Value (95% CI) p Value 
Year of reoperation 
As a continuous variable * 0.04 t NS * 0.44 t NS 
1993-1995 vs 1985-1992 1.77 0.08 ? NS 0.91 0.80 t NS 
(0.93, 3.35) (0.43, 1.92) 
Retransplantation ce ter 
Europe vs North America 1.47 0.24 t NS 1.48 0.31 t NS 
(0.78, 2.76) (0.70, 3.14) 
Type of reoperation 
All 5 types * 0.85 t NS * 0.21 t NS 
Old graft in situ vs not 0.85 0.63 t NS 0.54 0.14 t NS 
(0.45, 1.63) (0.23, 1.23) 
Total center volume 
->5 vs <5 retransplants 1.92 0.05 t NS 2.72 0.03 2.52 0.041 
(1.00, 3.72) (1.13, 6.58) (1.04, 6.15) 
Individual center experience 
>4th vs -<4th retransplant 1.56 0.17 t NS 1.29 0.52 t NS 
(0.82, 2.99) (0.59, 2.81) 
Identical match of donor- 1.81 0.13 t NS 1.59 0.33 t NS 
recipient ABO blood group (0.84, 3.93) (0.62, 4.10) 
Donor CMV negativity 1.71 0.11 t NS 1.89 0.10 t NS 
(0.89, 3.28) (0.87, 4.07) 
Donor-recipient CMV mismatch 0.60 0.29 t NS 0.42 0.19 -~ NS 
(0.23, 1.54) (0.12, 1.56) 
Odds ratios and adjusted odds ratios >1.0 indicate increased survival, whereas ratios <1.0 indicate decreased survival at 3 months and 2 years after 
retransplantation. C/, confidence interval; NS, not significant on multivariable analysis; CMV,, cytomegalovirus; OB, obliterative bronchiolitis. 
*Odds ratio not calculated because variable has more than two categories. 
tAdjusted odds ratio not calculated because variable does not enter into multivariable model. 
management system (Microsoft Corporation, Redmond, 
Wash.) on a Pentium/100 MHz computer. Statistical 
analysis was performed with the SAS statistical package, 
version 6.08 (SAS Institute Inc., Cary, N.C.). All data were 
expressed as mean plus or minus the standard error of the 
mean. Survival was calculated actuarially 15 and logistic 
regression methods 16 were used to determine which vari- 
ables were associated with early (3 month) and interme- 
diate-term (2 year) survival after retransplantation. Vari- 
ables exhibiting a p value less than 0.25 on marginal 
(single covariate) analysis were considered for entry into a 
multivariable model to determine the independent pre- 
dictors of survival after retransplantation. Furthermore, 
the odds ratio of each variable was expressed as a com- 
parison of survival between groups, with a value of 1.0 
indicating no survival difference, a value greater than 
1.0 indicating increased survival, and a value less than 1.0 
indicating decreased survival after retransplantation. 
A major focus of this article and our previous report s
was pulmonary function and the recurrence of bronchioli- 
tis obliterans syndrome (BOS) after retransplantation. 
Complete pulmonary function test data were therefore 
obtained prospectively from every survivor of retrans- 
plantation at 6- to 12-month intervals. BOS stages 
were assigned according to previously published criteria 
on the basis of postoperative values of forced expiratory 
volume in 1 second (FEV1). 17 The changes in absolute 
FEV 1 values at 1, 2, and 3 years after retransplantation 
were calculated for the entire study cohort, for single 
versus bilateral lung retransplant recipients, and for 
patients who underwent retransplantation because of 
OB versus those who underwent retransplantation be- 
cause of other conditions. Paired, two-tailed t tests were 
used to compare changes over time within each patient 
group. No adjustment was made for multiple compari- 
sons. Descriptive comparisons between patient groups 
indicated that variances were unequal and the FEVt 
data were therefore log transformed (to improve the 
equality of variances) before being compared by unpaired, 
two-tailed tests. TM In addition, contingency table analyses 
were used to compare the prevalence of stages 1, 2, and 
3 BOS between patient groups at 1, 2, and 3 years 
after retransplantation. A p value <0.05 was considered 
significant. 
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Fig. 1. Actuarial survival according to ambulatory status of recipient immediately before retransplanta- 
tion: n = 51 (ambulatory) versus 109 (nonambulatory);p = 0.01. 
Results 
Thirty-five lung transplantation centers partici- 
pated in this study, including 19 from North Amer- 
ica and 16 from Europe. The study cohort com- 
prised 160 retransplant recipients, including 92 
female and 68 male patients with a median age of 42 
years (range 6 months to 62 years). Before under- 
going the first transplantation 31% of patients had 
emphysema, 20% restrictive lung disease, 20% pri- 
mary pulmonary hypertension or Eisenmenger's 
syndrome, 17% cystic fibrosis, and 12% miscella- 
neous conditions. The indications for retransplanta- 
tion (and median interval between transplant pro- 
cedures) included OB in 93 cases (624 days), 
primary graft failure in 40 cases (13 days), intracta- 
ble airway complications in 14 cases (119 days), 
histologically confirmed severe acute rejection in 8 
cases (23 days), and miscellaneous conditions in 5 
cases (206 days). Forty patients (25%) underwent 
ipsilateral single-lung retransplantation, 28patients 
(18%) contralateral single-lung retransplantation, 
36 patients (23%) repeat double-lung transplanta- 
tion, 25 patients (15%) double-lung transplantation 
after a previous ingle-lung transplantation, and 31 
patients (19%) single-lung transplantation after a 
previous double-lung or heart-lung transplantation. 
Patient follow-up was 100% complete, with current 
survival and pulmonary function test data available 
in every patient. 
Survival. Of the retransplant recipients, 101 have 
died and 59 are still living. The 1-year actuarial 
survival was 45% 2 4% versus 35% _+ 5% in the first 
report from the retransplant registry 3 years ago. 5 
The 2-, 3-, and 4-year actuarial survivals were 
41% _+ 4%, 33% _+ 4%, and 30% _+ 4%, respec- 
tively. The median follow-up in current survivors is 
780 days (mean 894 _+ 74 days, range 41 to 2113 
days). Sixty-two patients have reached the first an- 
niversary, 39 the second anniversary, 27 the third 
anniversary, 13 the fourth anniversary, and 3 the 
fifth anniversary of retransplantation. 
Association of recipient variables with survival. 
The association of nine recipient-related variables 
with survival after retransplantation is shown in 
Table I. Survival was not significantly different ac- 
cording to the age, sex, original diagnosis, or cyto- 
megalovirus tatus of the recipient. Similarly, sur- 
vival did not differ according to the indication for 
retransplantation, the recipients' ventilator status 
before reoperation, or the official waiting time for a 
second lung graft. When analyzed as a continuous 
variable, a longer interval between operations was 
associated with increased 3-month, but not 2-year, 
survival after retransplantation. Immediately before 
retransplantation, only 32% of recipients were am- 
bulatory. These patients had a significantly im- 
proved 3-month survival after retransplantation 
both marginal and multivariable analyses and a 
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Fig. 2. Actuarial survival according to volume of retransplantation procedures done: n = 105 (5or more 
retransplants) versus 55 (fewer than 5 retransplants); p = 0.03. 
significantly better overall survival than nonambula- 
tory recipients on actuarial analysis (Fig. 1). Never- 
theless, on multivariable analysis no recipient vari- 
able was predictive of 2-year survival after 
retransplantation (Table I). 
Association of donor and operative variables with 
survival. The association of eight donor and oper- 
ative variables with survival after retransplantation 
is shown in Table II. When analyzed as a continuous 
variable, the year of retransplantation was associ- 
ated with 3-month, but not 2-year, survival. The type 
of retransplantation procedure, location of the re- 
transplantation center, donor cytomegalovirus sta- 
tus, presence of a donor-recipient cytomegalovirus 
mismatch, and presence of an identical match of 
donor-recipient ABO blood group did not have a 
significant impact on 3-month or 2-year survival 
after retransplantation. The total center volume of 
pulmonary retransplantation procedures was associ- 
ated with both 3-month and 2-year survival (Table 
II, Fig. 2) and was the sole variable that predicted 
2-year survival after retransplantation multivari- 
able analysis (odds ratio 2.52, 95% confidence inter- 
val 1.04 to 6.15,p = 0.041). 
Center effect. Because the data in this study were 
collected from 35 North American and European 
centers, there was a possibility that these data might 
be clustered. An adjusted logistic regression analysis 
was therefore performed, comparing the survival 
among larger centers with five or more patients who 
underwent ransplantation versus that in smaller 
centers with fewer than five retransplant recipients. 
For 90-day postoperative survival, the adjusted anal- 
ysis did not significantly change the odds ratios, 
confidence intervals, andp values of the 17 variables 
shown in Tables ! and II. For 2-year survival, 
however, the adjusted analysis disclosed that center 
of retransplantation had a significant effect. The 
adjusted multivariable analysis also resulted in am- 
bulatory status becoming a significant predictor of 
2-year survival (odds ratio 2.99, 95% confidence 
interval 1.10 to 8.09, p = 0.03), whereas ambulatory 
status was not a significant predictor of 2-year 
survival in Table I. Aside from ambulatory status, no 
new variable became significant in the adjusted 
analysis of center effect. 
Causes of death. Consonant with previous reports 
from the registry, 5-8 opportunistic nfection was the 
leading cause of death after retransplantation. Never- 
theless, with increased patient accrual and maturation 
of the registry database, the percentage of deaths 
caused by infection has decreased to42%, as opposed 
to greater than 50% in previous reports. Concomi- 
tantly, the percentage of deaths caused by recurrent 
OB has increased to 26%. An additional 26% of 
patients died as a result of acute failure of the second 
graft early after reoperation, 3% of an airway compli- 
cation, and 3% of miscellaneous causes. 
Functional status after retransplantation. After 
a median follow-up of 780 days, 53% of patients 
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show proportion of patients in each stage who underwent retransplantation because of OB, as opposed to 
other indications. 
were in New York Heart Association functional 
class I, 34% in class II, 10% in class III, and 3% in 
class IV. Fifty-one of the 59 survivors did not require 
supplemental oxygen whereas 8 patients were oxy- 
gen dependent. 
Pulmonary function and BOS stages in retrans- 
plantation survivors. Complete, up-to-date FEV I 
data were available from every retransplant recipi- 
ent who survived at least 1year after operation. Fig. 
3 shows the prevalence of BOS stages in these 
patients at 1, 2, and 3 years after retransplantation. 
Seventy-nine percent of all retransplant recipients 
were free of BOS (stages 1 to 3) at 1 year, 64% at 2 
years, and 56% at 3 years. The prevalence of stage 3 
(severe) BOS was 12% at 1 year, 15% at 2 years, and 
32% at 3 years after retransplantation, which is 
similar to that reported after primary lung trans- 
plantation.14, 19-21 With increasing duration of fol- 
low-up, patients who underwent retransplantation 
because of OB were represented disproportionately 
in the higher BOS stages, as compared with patients 
who underwent reoperation because of non-OB 
conditions (Fig. 3). By 3 years after retransplanta- 
tion, only 31% of patients who underwent retrans- 
plantation because of OB were free of BOS versus 
83% of patients who underwent retransplantation 
for other indications (p = 0.02). Subset analyses 
revealed that the interval between transplant oper- 
ations in patients with OB did not influence the 
prevalence of BOS at 2 (p = 0.10) and 3 years (p = 
0.53) after retransplantation. As shown in Fig. 4, the 
development of severe BOS had a negative impact 
on subsequent patient survival. Retransplant recip- 
ients in BOS stage 3 at 1 year had a significantly 
worse actuarial survival than those in BOS stages 0 
to 2 (p < 0.01). 
In the 27 recipients who survived beyond the third 
anniversary of retransplantation, FEV1 values de- 
creased by 2% at 1 year, 13% _+ 5% at 2 years (95% 
confidence interval 3.2% to 22.8%), and 19% ± 7% 
at 3 years (95% confidence interval 5.3% to 32.7%) 
versus postoperative baseline values (p = 0.02 at 3 
years). The absolute FEV 1 value at 2 years after 
retransplantation was associated with subsequent 
survival at 3 (p = 0.002) and 4 years (p = 0.01). 
Fig. 5 shows the changes in absolute FEV 1 values 
in 27 recipients who were followed up for 3 years 
after retransplantation. Patients who underwent re- 
transplantation because of OB had a significant 
decrease in FEV 1 values at 2 (p = 0.02) and 3 (p < 
0.01) years relative to the postoperative baseline 
value, whereas the FEV 1 value of patients who 
underwent retransplantation for other indications 
did not significantly change. Significant differences 
between groups were noted at 2 (p = 0.04) and 3 
years (p = 0.02). Fig. 6 depicts the changes in 
absolute FEV 1 values in patients who received a 
single-lung versus a bilateral-lung retransplant. A1- 
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though bilateral pulmonary retransplant recipients 
had a significantly higher FEV] value 3, 12, and 24 
months after operation, by3 years after retransplan- 
tation the FEV I values did not significantly differ 
between groups (p = 0.35). 
Discuss ion  
Despite significant progress in the management of
lung donors, 1in operative technique, and in postop- 
erative care 4 in recent years, the practice of lung 
transplantation remains constrained by a marked 
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shortage of donor organs. The pulmonary retrans- 
plant registry was established in 1991 to determine 
the outcome and predictors of survival after retrans- 
plantation and to promote the efficient use of scarce 
donor organs. Data from the International Society 
for Heart and Lung Transplantation Registry on 
more than 1000 single-lung transplant recipients 
have confirmed that a previous lung transplant in- 
creases the risk of 1-year mortality more than three- 
fold. 3 Many lung transplant programs accordingly do 
not offer recipients with acute or chronic graft failure 
the option of retransplantation. Nonetheless, ome 
centers have developed particular expertise in pulmo- 
nary retransplantation, with intermediate-term actuar- 
ial survival rates only slightly lower than those after 
primary lung transplantation. 11' 13,14 To make optimal 
use of scarce donor lung grafts, it is important o 
determine whether the pulmonary function of surviv- 
ing retransplant recipients i  preserved as well as that 
in recipients of first-time lung grafts. 
Since the previous report from the retransplant 
registry in 1995, 8 21 new patients have been re- 
cruited and the registry database has matured. All 
patients are currently being followed up prospec- 
tively, with 6- to 12-month updates of pulmonary 
function and clinical status. The median follow-up in 
surviving patients is now 780 days, versus 630 days in 
our previous report. Furthermore, the number of 
3-year survivors after retransplantation has almost 
doubled and the number of 4-year survivors has 
more than tripled. The increasing duration of fol- 
low-up in retransplantation survivors has resulted, 
for the first time, in significant differences in BOS 
stage and FEV 1 values between patient groups. 
Multivariable analyses of 3-month survival have 
confirmed the cardinal importance of ambulatory 
status in predicting early outcome after retransplan- 
tation. The 32% of patients who were ambulatory 
immediately before retransplantation had almost a 
threefold increased likelihood of postoperative sur- 
vival. In view of the marked scarcity of donor lung 
grafts, we therefore believe that lung retransplanta- 
tion should be limited to ambulatory patients. By 
single covariate analysis, a longer interval between 
transplant procedures was associated with increased 
early survival, consonant with the recently published 
University of Vienna experience 22and the interna- 
tional experience after cardiac retransplantation. 3 
However, this factor was not significant on multiva- 
riable analysis, indicating that some of its associa- 
tion with early survival may have been a result of the 
confounding effects of other variables, such as am- 
bulatory status. Further patient accrual and a longer 
follow-up of registered patients should provide a 
more precise indication of the relation of the inter- 
val between transplantation procedures to survival 
after retransplantation. 
Recently, the Harefield experience of 27 single- 
lung retransplantations i  patients with OB has been 
reported. 23 The 1-year actuarial survival after single- 
lung retransplantation was 56% -+ 9%, which com- 
pares favorably with the 27% 1-year survival after 
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repeat heart-lung transplantation that has been 
noted in data from the International Society for 
Heart and Lung Transplantation Registry. 3 A mul- 
tivariable analysis of the Hare field data revealed 
that ambulatory recipients, patients who were not 
receiving mechanical ventilation at the time of re- 
transplantation, and those who had a long interval 
between transplantation procedures were most 
likely to have a good outcome. 23 These data corrob- 
orate the findings of the pulmonary retransplant 
registry, although in our experience with 160 re- 
transplant recipients the lack of requirement for 
ventilatory support before reoperation was not sig- 
nificantly related to 3-month survival by marginal or 
multivariable analysis (Table I). 
Because the median duration of follow-up in 
postoperative survivors was greater than 2 years in 
our study, a separate analysis was performed to 
determine the factors associated with and predictive 
of 2-year survival. As shown in Table I, no recipient 
variable was predictive of intermediate-term sur- 
vival; however, when adjusted for a possible center 
effect, ambulatory status became a significant pre- 
dictor of 2-year survival. As indicated in Table II, 
more recent year of reoperation and a total center 
volume of five or more retransplantation procedures 
were significantly associated with 3-month survival. 
However, the effect of year of retransplantation was 
less prominently associated with survival than in 
previous studies. 7's On multivariable analysis, no 
donor or operative variable was associated with 
early survival after retransplantation; nevertheless, a 
total center volume of five or more retransplanta- 
tion procedures predicted increased 2-year survival. 
Interestingly, the odds ratio favoring survival in 
high-volume centers was higher in the 2-year, rather 
than 3-month, survival analysis (Table II). This 
illustrates that increasing experience with pulmo- 
nary retransplantation is associated not only with 
decreased operative mortality, but also with in- 
creased expertise in patient reatment and improved 
results in the intermediate rm after retransplanta- 
tion. 
Analysis of the pulmonary function and BOS data 
confirmed that patients who underwent retransplan- 
tation because of OB had more significant pulmo- 
nary dysfunction in the intermediate term after 
operation than those who underwent retransplanta- 
tion for other indications. Because most patient 
mortality occurred early after retransplantation, ac- 
tuarial survival was not significantly different be- 
tween the OB and non-OB recipients (Table I). 
Furthermore, the differences in BOS stage and 
FEV1 values between OB and non-OB recipients 
became apparent only 2 years after operation and 
were significant after 3 years of follow-up (Figs. 3 
and 5). Because retransplant recipients in BOS stage 
3 at 1 and 2 years had a significantly worse actuarial 
survival than those in BOS stages 0 to 2, further 
patient follow-up may result in significant differ- 
ences in survival between OB and non-OB retrans- 
plant recipients. 
The results of this study indicate that improved 
management strategies are indeed necessary to pre- 
vent the development of progressive graft dysfunc- 
tion after retransplantation because of OB. Re- 
cently, several lung transplant programs have 
accrued experience with the use of cytolytic thera- 
py24 and methotrexate 25 to treat evolving BOS after 
primary lung transplantation. Furthermore, the use 
of tacrolimus, as opposed to cyclosporine, as the 
main immunosuppressive agent after primary lung 
transplantation has shown promise, 26 although a 
decrease in the prevalence of BOS as a result of 
tacrolimus therapy has yet to be conclusively dem- 
onstrated. Currently, the Hannover group TM and 
other lung transplantation programs are investigat- 
ing the use of tacrolimus as the principal component 
of an alternative immunosuppressive regimen after 
retransplantation. Data on immunosuppressive pro- 
tocols are being prospectively entered into the re- 
transplant database to determine whether newer 
agents have an impact on the high rate of recurrent 
OB in patients who undergo retransplantation be- 
cause of this complication. We hope that with 
improved selection of retransplant candidates, in- 
creased experience in reoperative techniques, and 
the evolution of new immunosuppressive protocols, 
the results of retransplantation will improve so that 
actuarial survival after these procedures can approx- 
imate that after primary lung transplantation. 
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Discuss ion 
Dr. Bruce A. Reitz (Stanford, Calif.). This is a further 
communication from the pulmonary retransplant registry, 
and the data now are becoming more valuable with the 
longer-term follow-up that is now available. I think the most 
encouraging finding of this report is that there is an improv- 
ing 1-year survival in these retransplantation cases, now at 
45% overall, up from about one third a year ago in the 
previous report. The current finding of a center effect, 
namely, that more than five retransplants is related to 
improved long-term survival, suggests that a learning curve 
exists. It is not clear to me, however, why this is exactly so. In 
cardiac transplantation, retransplantation because of early 
graft failure has always had a much worse prognosis than 
retransplantation because of coronary artery disease. Can 
the authors comment on the fact that recipient retransplan- 
tation indication was not significant? Is it obscured by the 
interval between transplants or by relatively fewer retrans- 
plants for graft failure being done? Could the learning curve 
be a result of those centers doing more retransplants devel- 
oping a better idea of who the ideal candidate should be for 
retransplantation? 
The second important finding is that beyond 3 
months, the survival of these patients is close to that of 
patients with primary transplants. In the late follow-up, 
the recurrence of OB in patients who underwent re- 
transplantation because of this indication is disappoint- 
ing but not surprising. The only progress in the area of 
OB will come with better immunosuppression; perhaps 
tolerance induction or some undefined treatment. In 
this regard, in a model of tracheal transplantation in 
rats simulating OB in Dr. Morris' lab at Stanford, we 
have found that both rapamycin and leflunomide are 
significantly better than cyclosporine or tacrolimus in 
preventing OB-like lesions. Perhaps the microchimer- 
ism being studied at Pittsburgh will also be helpful. 
Thus we hope the need for retransplantation and these 
worse outcomes in patients who undergo retransplan- 
tation will be improved in future years. 
Inevitably the question comes up of whether etrans- 
plantation should be done at all because donor lungs are 
scarce; this point was made earlier, and waiting lists are 
increasing. Given the results presented, some might con- 
clude that retransplantation should not be done. I person- 
ally believe that this is the decision of a local program, 
with some choosing to offer retransplantation and others 
not. However, I would like to ask the authors' thoughts on 
this issue and whether they had queried the 35 centers on 
their recent or current policies with respect o retrans- 
plantation. 
Dr. Novick. Thank you, Dr. Reitz. Concerning the issue 
of retransplantation ce ter volume, we examined each of 
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the 17 other variables that we studied, and none of them 
had an impact on the differing results een in centers with 
experience with five or more versus fewer than five 
retransplantations. We believe that the improved results 
from the former centers reflect a learning curve, in terms 
of not only how to safely perform retransplantation pro- 
cedures but also how to take care of these patients in the 
intermediate rm after operation. 
Concerning the issue of alternative immunosuppressive 
regimens, I believe that this is a key factor. It may well be 
that patients who undergo retransplantation because of 
OB should be given one of the newer immunosuppressive 
agents after operation. Data on immunosuppressive pro- 
tocols after retransplantation are being collected prospec- 
tively in our database, and we await the result of future 
analyses of these data with interest. 
Finally, concerning the appropriateness of pulmonary 
retransplantation, I believe that the registry results indi- 
cate that retransplantation should only be done in select 
centers with experience in retransplantation. Further- 
more, pulmonary retransplantation should be performed 
in patients who are ambulatory and who are maximally 
able to benefit from the procedure. In our initial study 
published 3years ago we asked each contributing surgeon 
whether he or she would perform a retransplantation 
again in these patients; 75% of the polled surgeons 
responded in the affirmative. 
Dr. Shaf Keshavjee (Toronto, Ontario, Canada). Did the 
authors analyze the data with respect to survival of single- 
versus double-lung transplants in retransplantation? 
Dr. Novick. Yes, we did. There was no survival differ- 
ence according to the type of retransplantation procedure 
that was performed. In 37% of cases, an old contralateral 
graft was left in situ after retransplantation. I  previous 
years, this factor tended to be associated with worse 
survival; however, with an increasing number of patients 
in the registry, it is now clear that patients with and 
without an old retained contralateral graft have similar 
actuarial survival and pulmonary function in the interme- 
diate term after operation. 
Appendix: Participating centers 
United States. Stanford University Medical Center, Stan- 
ford, Calif.; Loyola University Medical Center, Maywood, 
Ill.; University of Iowa Hospital, Iowa City, Iowa; Brigham 
and Women's Hospital, Boston, Mass.; University of Mich- 
igan Medical Center, Ann Arbor, Mich.; University of 
Minnesota Health Center, Minneapolis, Minn.; Washington 
University Medical Center, St. Louis, Mo.; St. Louis Chil- 
dren's Hospital, St. Louis, Mo.; University of North Carolina 
Medical Center, Chapel Hill, N.C.; University of Pennsylva- 
nia Hospital, Philadelphia, Pa.; University of Pittsburgh, 
Presbyterian Hospital, Pittsburgh, Pa.; Vanderbilt University 
Medical Center, Nashville, Tenn.; Baylor-Methodist Hospi- 
tal, Houston, Tex.; University of Texas Medical Center, San 
Antonio, Tex.; University of Virginia Medical Center, Char- 
lottesville, Va.; and University of Wisconsin Medical Center, 
Madison, Wis. 
Canada. Toronto Hospital, Toronto, Ontario; Mon- 
treal General Hospital, Montreal, Quebec; and Centre for 
Health Sciences, Winnipeg, Manitoba. 
Europe. Allegemeine Krankenhaus, Vienna, Austria; 
Hopital Erasme, Brussels, Belgium; Rigshospitalet, Copen- 
hagen, Denmark; Papwolth Hospital, Cambridge, England; 
Freeman Hospital, Newcastle upon Tyne, England; Helsinki 
University Central Hospital, Helsinki, Finland; Hopital 
Beaujon, Clichy, France; Centre Hospitalier Universitaire de 
Grenoble, Grenoble, France; Hopital d'Enfants de la 
Timone, Marseille, France; Hopital Xavier Arnozan, Pessac, 
France; Centre Medico-Chirurgical Foch, Suresnes, France; 
Medizinische Hochschule Hannover, Hannover, Germany; 
Klinikum Grof3hadern, Munich, Germany; Academisch 
Ziekenhuis Groningen, Groningen, Holland; Rikshospitalet, 
Oslo, Norway; and Universitatsspital Zurich, Zurich, Swit- 
zerland. 
